Gene Editing Trial Under Scrutiny After Boy's Tragic Death
By Editor • August 19, 2026 • 1 min read
Following a boy's fatal incident in Huidagene's gene editing trial, experts are evaluating the company's scientific approach. Alvin Luk, the former CEO, had previously shared preliminary data at a major symposium.
Experts reviewing the presentation expressed mixed opinions on Huidagene's scientific integrity. Dongsheng Duan, a gene editing researcher, remarked, “I’m not impressed,” highlighting concerns over the trial's methodology.
Source: www.statnews.com
#Alvin Luk #clinical trial #Duchenne #gene editing #Huidagene
